Pacira BioSciences (PCRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PCRX Pacira BioSciences

Watchlist

15.300
+0.250+1.66%

Close Oct 1 16:00 ET

15.250
-0.050-0.33%

Pre 07:09 ET

705.74MMarket Cap11.42P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Executive Reshuffles: NSC, PCRX and OMI Companies in Focus
Seeking AlphaSep 28 15:54 ET
Pacira BioSciences Appoints Lauren Riker as Interim CFO
Seeking AlphaSep 27 14:00 ET
Express News | Pacira Biosciences Inc: Board Appointed Lauren Riker as Interim Chief Financial Officer
ReutersSep 27 08:04 ET
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
GlobeNewswireSep 26 08:00 ET
Pacira BioSciences Urged to 'Aggressively' Buy Back Shares to Enhance Return
MT NewswiresSep 25 09:55 ET
DOMA Perpetual Sends Letter To Board of Directors Of Pacira Biosciences To Immediately Accelerate And Increase Its Share Buyback Program To Enhance Return To Shareholders; Believes Pacira's Cash Balance Of $400M, Roughly 59% of Its Market...
BenzingaSep 25 08:17 ET

Comments

Value investorr

Aug 23 11:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

Value investorr

Aug 19 10:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

Mr Long Term

Aug 13 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Value investorr

Aug 12 09:29

A golden opportunity

$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...